Infectious disease
In addition to the COVID-19 development, the company plans to use the proceeds toward its pipeline of highly selective direct acting antivirals that target other severe RNA virus infections.
Weeks after Mammoth Biosciences announced its CRISPR-based diagnostics test for COVID-19 had a high degree of specificity even for asymptomatic patients, the company has struck a deal with GSK to accelerate development of the test in hopes of getting them in consumer hands as soon as possible.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 20, 2020.
Research conducted under the collaboration will support FDA objectives to explore the natural history of the disease, as well as treatment and diagnostic patterns through the use of relevant and new data sources.
Expected to launch in June or July, the study plans to test as many as 325,000 people to learn how the SARS-CoV-2 virus is spreading nationally, according to Reuters, reporting before the official announcement.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 19, 2020.
U.S. demand for telehealth will soar by 64.3% in 2020 because of the COVID-19 pandemic, according to a report released by Frost & Sullivan.
AstraZeneca reported it plans to manufacture as much as 30 million doses of the vaccine for the U.K. market by September, with expectations of 100 million doses by the end of the year.
Moderna released positive interim Phase I data from its clinical trial of mRNA-1273, its mRNA vaccine against SARS-CoV-2.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 18, 2020.
PRESS RELEASES